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Abstract
working by a distinct cell wall-specific mechanism of
action, the echinocandin class of antifungals has sub-
stantially expanded the range of available treatments
for invasive Candida infections. anidulafungin, caspo-
fungin and micafungin were investigated versus drugs
from  earlier  antifungal  classes  in  large  clinical  trials
that demonstrated their excellent clinical and microbi-
ological efficacy in the primary treatment of invasive
candidiasis. Therefore, and supported by a number of
favourable pharmacological characteristics, the echino  -
candins rapidly became established in guidelines and
clinical practice as primary treatment options for mod-
erately to severely ill patients with invasive candidiasis.
This article reviews the relevant clinical evidence that
forms the basis for the use of echinocandins in the
management  of  invasive  candidiasis,  and  discusses
their current role in the context of recent guideline
recommendations  and  treatment  optimization  strate-
gies.
InTRoduCTIon
Candida spp. are prominent fungal pathogens causing
invasive infections predominantly in neutropenic and
severely  ill  non-neutropenic  patients.  Most  patients
with invasive candidiasis have candidemia without evi-
dence of deep tissue or organ involvement. despite
efforts to advance treatment options and modalities,
the  mortality  associated  with  invasive  candidiasis  is
still high. Published figures of crude mortality reside
in the range of 30-60%, attributable mortality is esti-
mated at 25-40% [1-6].
as  several  investigators  have  shown,  mortality  of
candidemia is directly correlated with the delay of ini-
tiation of adequate antifungal therapy [7, 8]. Thus, ear-
ly  treatment  with  a  reliably  active  and  safe  drug  is
mandatory to achieve the optimum clinical outcomes.
However, this is a difficult requirement to meet as the
predominant  challenges  encountered  in  the  manage-
ment of invasive candidiasis include a lack of well-per-
forming methods for early detection of infection and
several shortcomings of the azole and polyene anti-
fungals, the former mainstays of invasive candidiasis
therapy. These include gaps in the antifungal spectrum
and a multitude of drug interactions for the azoles,
and  nephrotoxicity  or  acute  toxicity  associated  with
the polyene antifungals.  
Beginning  in  2002,  the  introduction  of  three
echinocandin  antifungals  has  significantly  expanded
the historically limited armamentarium of drugs avail-
able for the treatment of invasive candidiasis. working
by a distinct cell wall-specific mechanism of action,
anidulafungin, caspofungin and micafungin are charac-
terized by excellent antifungal activity against Candida
spp. and Aspergillus spp., low toxicity, few or negligi-
ble drug-drug interactions and pharmacokinetic inde-
pendence  of  renal  (and  mostly  hepatic)  function.
Therefore  they  rapidly  became  established  in  guide-
lines and clinical practice as primary treatment options
for severely ill patients with invasive candidiasis. after
a brief overview of the epidemiology and characteris-
tics of invasive candidiasis, this article reviews current
published  data  on  the  use  of  echinocandins  in  the
management of invasive Candida infections.
InvasIvE CandIdIasIs
as pointed out above, invasive Candida infections are
important  opportunistic  infections.  In  the  recent
EPIC II survey performed in 667 European intensive
care  units,  Candida  spp. were  involved  in  18.5%  of
cases with nosocomial infections [9]. according to an-
other recent survey at the intensive care units of 310
german  hospitals  [10],  fungal  pathogens  were  in-
volved in every fifth patient with infection, in the sub-
set of university hospitals Candida spp. were detected
in 24% of the infections.
In a large survey with 24,000 cases of bloodstream
infections in us hospitals [4], Candida spp. were the
fourth most common pathogen involved in sepsis at
an  incidence  of  4.6  cases  per  10,000  admissions.  a
multi-institutional survey performed by the European
Confederation of Medical Mycology in several Euro-
pean countries reported incidences of 2.0-3.8 cases of
candidemia per 10,000 admission and 0.30-0.41 cases
per 10,000 patient hospital days. The majority of the
cases  was  diagnosed  on  surgical  and  intensive  care
wards (48.2% and 40.2%, respectively), 22.5% of the
patients had solid tumors, 17.4% received steroids and
12.3% had hematological malignancies [11].  
This  distribution  reflects  the  predisposing  factors
identified by several authors [12], including neutrope-
nia, cancer chemotherapy, colonization with Candida
spp.,  exposure  to  broad  spectrum  antibiotics,  in-
dwelling central venous catheters, hemodialysis or re-
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tion,  prior  surgery,  particularly  gastro-abdominal
surgery  [13],  gastrointestinal  perforation  and  higher
age.  another  important  risk  group  are  solid  organ
transplant  recipients  receiving  immunosuppressants
[14]. Premature birth is a major predisposing factor in
neonates [12]. for intensive care patients, the rate of
invasive fungal infections increases with the duration
of stay, particularly >7 days [15].
among patients with malignant haematological dis-
eases, the highest rates of invasive Candida infections
are found in patients with neutropenia due to induc-
tion  chemotherapy  for  acute  leukemia  or  myelodys-
plastic syndrome and in recipients of allogeneic blood
stem cell transplants in the early post-transplant phase
and in periods of graft-versus-host disease (gvHd)
[16, 17].
while the majority of invasive Candida infections
are blood stream infections, organ involvement after
hematogeneous  dissemination,  peritonitis  and  endo-
carditis [18] are important manifestations of disease.
Candida endophthalmitis may develop in patients with
delayed  pathogen  clearance  from  the  blood  stream
(persistent candidemia).  
anTIfungal aCTIvITy of ECHInoCandIns In
ClInICally RElEvanT CAndidA spp.
The echinocandins are semisynthetic lipopeptides de-
rived from natural metabolites produced by three dif-
ferent fungi [19]. Their almost identical central hexa-
peptide structure carries substance-specific lipophilic
n-acyl side chains. This may be the basis of some dif-
ferences in terms of antifungal activity, pharmacoki-
netics, metabolism, tissue distribution and interactions.   
In  contrast  to  azole  and  polyene  antifungals,  the
echinocandins inhibit the synthesis of 1,3-beta-d-glu-
can, an essential polysaccharide component of the cell
wall in Candida spp. and Aspergillus spp. In Candida
spp., the deprivation of this major structural element
leads to disruption of the cell wall and subsequent cell
lysis,  accounting  for  the  fungicidal  activity  against
many Candida isolates at adequate concentrations [20].
The echinocandins show rather similar in  vitro anti-
fungal  activity  with  largely  overlapping  minimal  in-
hibitory  concentration  ranges  for  clinically  relevant
species [21]. MICs against C. albicans, C. glabrata, C.
tropicalis and C. krusei are usually significantly lower
that  those  observed  for  C.  parapsilosis or  the  rare
species C. guilliermondii. However, this divergence ap-
parently does not translate into clearly significant dif-
ferences in clinical activity. In a recent meta-analysis,
the  treatment  success  rate  in  202  patients  with  C.
parapsilosis infection from five studies was very simi-
lar  for  echinocandins  and  non-echinocandin  drugs
(76.3% vs. 73.0%) [22].
Recently proposed modifications of clinical inter-
pretive  breakpoints  for  echinocandin  susceptibility
testing of Candida spp. reflect this fact: C. parapsilosis
breakpoints are at least three dilution steps higher than
those of other Candida species, based on the fact that
isolates carrying resistance mechanisms are associated
with  much  higher  MIC  levels  in  C.  parapsilosis vs.
other species [23]. 
despite increasing use over the last decade, resis-
tance against echinocandins still remains rare and is
largely restricted to de novo emergence in patients with
longer treatment duration [24]. This is reassuring, giv-
en the fact that point mutations in the target enzyme
subunit  may  suffice  for  resistance  induction  [25].
Cross-resistance  among  echinocandins  is  the  rule,
while caspofungin-resistant isolates remaining suscep-
tible  to  anidulafungin  and/or  micafungin  have  been
observed [26, 27]. 
PHaRMaCoKInETIC PREMIsEs
due to a lack of oral bioavailability, the echinocandins
are exclusively parenteral drugs administered via intra-
venous infusion over 1-2 hours. Recommended infu-
sion rates should not be exceeded to avoid systemic
infusion reaction.
anidulafungin  and  micafungin  show  linear  dose-
plasma exposure relationships while caspofungin ex-
hibits  some  degree  of  non-linearity  in  the  clinically
useful range [28, 29]. all echinocandins exhibit some
degree of enrichment versus plasma in organs relevant
to invasive candidiasis (liver, kidneys, spleen, lungs). In
animal models, micafungin enriches 2-3 fold in these
organs [30], caspofungin mainly targets the liver and to
a lesser extent the kidneys [31] while anidulafungin ex-
hibits rather uniform enrichment (9-12 fold) in all four
organs [32]. none of the echinocandins reaches ade-
quate  levels  in  the  cerebrospinal  fluid,  intraocular
compartments or urine, making them less suited for
treatment of infections involving these sites [33-35]. 
anidulafungin  is  exclusively  degraded  be  sponta-
neous chemical processes and possibly by nonspecific
peptidases  in  the  plasma  [36],  whereas  the  other
echinocandins are metabolized to some extent in the
liver  via  n-acetylation  or  by  the  catechol-o-methyl-
transferase [37]. This may entail dose adjustment, re-
strictions of use or drug interactions.
dosagE ConsIdERaTIons
anidulafungin  is  used  at  a  uniform  dosage  of  100
mg/d (preceded by one 200 mg loading dose on day 1)
[38] for all patients regardless of body weight, organ
functions, age, or comedications [39-41]. anidulafun-
gin can be used at the same dose in patients with all
levels of hepatic insufficiency [40]. 
Caspofungin dosage must be adjusted according to
body weight and liver function. In addition, patients
on  treatment  with  inducers  of  hepatic  metabolism
must receive higher doses [42]. The standard dosage is
50 mg/d (after an initial loading dose of 70 mg on day
1). Patients weighing >80 kg should receive 70 mg/d
as  maintenance  dose.  larger  doses  of  caspofungin
(150 mg/d) have been used in a clinical trial on inva-
sive candidiasis. no significant differences or toxicity
or efficacy vs. standard doses were noted [43]. Moder-
ate liver insufficiency (Child-Pugh score 7-9) requires
a reduction of the maintenance dose to 35 mg/d [44].
Caspofungin should not be used in patients with se-
vere hepatic insufficiency (Child-Pugh score >9) [29]. 
Micafungin dosage is dependent of the purpose of
treatment (therapy vs. prophylaxis) [45, 46] and body
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dosage  compared  to  prophylactic  treatment.  In  pa-
tients weighing ≤40 kg micafungin must be dosed per
kg body weight (2 mg/kgﾷd or 1 mg/kgﾷd for prophy-
laxis), whereas heavier patients receive a fixed dosage
of  100  mg/d  (or  50  mg/d  for  prophylaxis).  The
dosage may be doubled in patients with insufficient
initial response. 
Micafungin doses are independent of organ func-
tions. However, the drug should not be used in pa-
tients with severe liver insufficiency due to a lack of
data [47]. 
dRug-dRug InTERaCTIons
generally,  the  echinocandins  are  characterized  by  a
low potential of drug-drug interactions, a feature that
is clearly a novelty in the field of antifungals that no-
toriously  involved  multiple  pharmacokinetic  (azoles)
[48]  or  problematic  pharmacodynamic  interactions
(polyenes) [49]. 
Primarily owing to the absence of any hepatic me-
tabolism [36], no clinically relevant interactions have
been  described  for  anidulafungin  [50-52],  the  drug
may thus be used at a fixed dose regardless of any
comedications [41]. 
due to its hepatic metabolism, caspofungin mainte-
nance dosages should be increased to 70 mg/d in pa-
tients concomitantly receiving enzyme inducers such
as  rifampicin,  dexamethasone,  phenytoin,  or  carba-
mazepine [42]. other potential interactions of caspo-
fungin involve immunosuppressants: the comedication
of caspofungin and ciclosporin a has been associated
with liver function abnormalities in healthy volunteers,
therefore  patients  receiving  both  drugs  should  be
monitored  for  liver  damage,  whereas  a  retrospective
review of patients treated with the combination did
not find evidence of enhanced clinically significant he-
patotoxicity [29, 53]. In addition, caspofungin increas-
es the trough levels of tacrolimus [54]; plasma level
monitoring and appropriate dose adjustments are re-
quired [29]. 
Micafungin increases the exposure of amphotericin
B requiring risk/benefit analysis and close monitoring
of amphotericin B toxicity. In addition micafungin in-
creases the exposures of itraconazole, sirolimus and
nifedipine, requiring monitoring and dose reduction as
appropriate [47]. 
ClInICal TRIals on TREaTMEnT of InvasIvE
CAndidA InfECTIons
The discussion in this section is mainly focussed on
well-conducted  large,  prospective  trials.  studies  with
small patient numbers or retrospective trials were not
included due to their limited evidence level and ambi-
guities of clinical interpretation.  
PIvoTal TRIals
The clinical efficacy and safety of all three echinocan-
dins  was  investigated  in  randomized  double-blinded
multicenter trials primarily involving non-neutropenic
adult patients with candidemia (Table 1) [45, 55-57].
Two studies used prevalidated comparator regimes –
anidulafungin was studied versus fluconazole [55] and
caspofungin  was  tested  versus  conventional  ampho-
tericin B [56]. an earlier randomized study had estab-
lished  the  therapeutic  noninferiority  of  fluconazole
versus amphotericin B [58]. Micafungin, however, was
initially investigated vs. liposomal amphotericin B that
had not been studied in a randomized trial for this in-
dication [57]. Regulatory authorities therefore request-
ed a second study of micafungin versus caspofungin
[45]. 
all but one study had a primary endpoint of com-
bined clinical-microbiological response at the end of
intravenous therapy in the modified intention-to-treat
(MITT) population, i.e. patients with initial detection
of Candida spp. in blood or other physiologically ster-
ile sites, and receipt of at least 1 dose of study medica-
tion.  The  trial  of  micafungin  vs.  liposomal  ampho-
tericin B [57] primarily analyzed patients treated for at
least 5 days which lead to numerically high success lev-
els in both groups by elimination of patients with ear-
ly discontinuation or failure. The MITT analysis for
non-inferiority was a secondary endpoint in this trial.
with the exception of the micafungin vs. liposomal
amphotericin B trial, all studies allowed for a switch to
oral fluconazole after at least 10 days of intravenous
study treatment.
all three trials involving caspofungin and micafun-
gin  the  non-inferiority  of  the  experimental  drug  vs.
comparator: caspofungin was as effective as ampho-
tericin B and micafungin was non-inferior to liposo-
mal amphotericin B and caspofungin. There were no
significant  mortality  differences  between  the  respec-
tive study arms [45, 56, 57]. 
The  trial  of  micafungin  vs.  caspofungin  [45]  in-
volved two micafungin dose regimens (100 mg/d and
150  mg/d)  that  showed  similar  efficacy,  establishing
100 mg/d as the standard dose in this indication. The
global success rates in patients with C. glabrata infec-
tions were approximately 20% higher in the micafun-
gin vs. caspofungin groups, whereas the difference was
not statistically significant.    
In contrast to the other trials, the protocol of the
study comparing caspofungin vs. amphotericin B de-
oxycholate [56] defined a change of therapy due to
toxicity as failure. This caused an inherent imbalance
in  favour  of  caspofungin  since  the  well-known
nephrotoxicity of amphotericin B necessitated the dis-
continuation of this study drug in a high proportion
of  patients  (16.5%  versus  2.8%  in  the  caspofungin
arm). 
The trial of anidulafungin versus fluconazole [55]
was the first randomized study in invasive candidiasis
to establish a significant difference in the primary end-
point favouring a new drug versus an established op-
tion. The global success rate at the end of intravenous
therapy was 76% for anidulafungin vs. 60% for flu-
conazole.  The  difference  was  statistically  significant
(95% confidence interval 3.9-27.0). according to the
same  criteria,  anidulafungin  had  significantly  higher
success rates at the end of all therapy and at the fol-
low-up  visit  2  weeks  after  the  end  of  therapy.  The
higher global efficacy of anidulafungin may be due to
a  faster  clearance  of  the  pathogens  from  the  blood
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median of 2 days in patients receiving anidulafungin
vs. 5 days in the fluconazole arm [59]. Persistent Can-
dida infection at the end of intravenous therapy was
observed in 6.3% vs. 14.4% of patients. The robust-
ness of these data was shown by the analysis of sub-
populations with risk factors for an unfavourable out-
come: anidulafungin achieved higher success rates in
intensive care patients, patients with single and multi-
ple organ failure and/or severe sepsis, higher age, and
retained central venous catheters [60].
The results of this trial established that anidulafun-
gin – and potentially the echinocandins in general –
may provide a relevant clinical benefit versus the long-
standing standard candidemia drug fluconazole. This
advantage may be used to the benefit of more severely
ill patients in clinical routine, a notion that is reflected
in  current  guideline  recommendations  on  the  treat-
ment of invasive Candida infections.  
fuRTHER sTudIEs
The database of anidulafungin was recently expanded
in a non-comparative multicenter phase IIIb trial (ICE
study)  [61]  exclusively  involving  adult  intensive  care
patients with invasive Candida infection and at least 1
additional  risk  factor,  e.g.  abdominal  surgery,  organ
transplant, or neutropenia. 29% of the 170 patients
had  invasive  infections  involving  non-bloodstream
body sites. Patients were allowed to switch to oral flu-
conazole or voriconazole after at least 10 days of in-
travenous therapy. The success rates at the end of in-
travenous therapy and further time points were com-
parable to the results of the pivotal trial, confirming
the efficacy of anidulafungin for severely ill patients
with invasive candidiasis including those with tissue or
organ involvement (fig. 1).
another multicenter study investigated the use of
caspofungin as primary or salvage treatment in inva-
sive candidiasis involving non-bloodstream body sites.
Patients  with  peritonitis,  intraabdominal  abscesses,
chronic-disseminated candidiasis, or multilocular inva-
sive candidiasis received the standard 50 mg/d caspo-
fungin dose, patients with osteomyelitis, septic arthri-
tis, or endocarditis were treated with a higher dosage
(100 mg/d) [62]. These dosages could be escalated to
100 mg/d or 150 mg/d, respectively, in cases with in-
adequate response. The overall success rate was 81%,
ranging  from  33%  (1/3)  for  endocarditis  to  100%
(4/4) for osteomyelitis or septic arthritis. overall mor-
tality was 23% at 12 weeks. The elevated dosage of
100 mg/d was well tolerated.
Colombo et al. [63] analyzed the data of 212 pa-
tients with C.  non-albicans infections (predominantly
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Table 1. Results in the MITT populations of pivotal trials of echinocandins for therapy of invasive fungal infections [45, 55-57]. 
Anidulafungin Caspofungin Micafungin
Comparator fluconazole amphotericin B  liposomal  Caspofungin ****
deoxycholate amphotericin B
Patient number (MITT), n 127 / 118 109 / 115 247 / 247 191 / 188
Candidemia, % 91 / 87 82.6 / 79.1 84.2 / 85.8 *** 85.3 / 85.6
Infection with C. non-albicans, % 36 / 41 * 64.4 / 45.9 62.4 / 58.9 *** 54.5 / 60.6
[p = 0.0009]
neutropenia, % 2.4 / 3.4 12.8 / 8.7 11.9 / 7.9 *** 11.5 / 5.9
switched to oral fluconazole, % 26.0 / 28.0 24.8 / 34.8 not allowed 20.9 / 21.2
global success at end of Iv therapy, % 75.6 / 60.2 73.4 / 61.7 74.1 / 69.6 76.4 / 72.3
[p = 0.01] [p = n.s.] [p = n.s.] [p = n.s.]
global success at end of all therapy, % 74.0 / 56.8 72.5 / 61.7 74.1 / 69.6 74.9 / 70.2
[p < 0.02] [p = n.s.] [p = n.s.] [p = n.s.]
global success at 2 weeks follow up, % 64.6 / 49.2 63.6 / 53.8 not reported 54.5/ 50.5
[p < 0.02] [p = n.s.] [p = n.s.]
global success at 6 weeks follow up, % 55.9 / 44.1 56.6 /47.5 ** not reported 46.6 / 42.6
[p = n.s.] [p = n.s.] [p = n.s.]
Microbiological success at end of Iv  88.1 / 76.2 not reported not reported 88.5 / 84.0
therapy, %
Time to negative blood cultures, days 2 / 5 not reported 3 / 4 *** 2 / 2
(C. albicans)[59] 
Persistent infection, % 6.3 / 14.4 8.3 / 8.7 8.9 / 8.4 *** 5.8 / 9.6
[p = n.s.] [p = n.s.] [p = n.s.] [p = n.s.]
Mortality rate (ITT), % 22.8 / 31.4 34.2 / 30.4 40 / 40 29.0 / 26.4
[p = n.s.] [p = n.s.] [p = n.s.]
* Patients with C. krusei infection were excluded from the trial.
** follow-up at 6-8 weeks after end of all therapy.
*** In the per-protocol set.
**** Column excludes results of micafungin 150 mg arm. 
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from the caspofungin clinical trials database, indicating
response rates in the range of infections with C. albi-
cans (at least 70%). 
a recent randomized trial compared caspofungin at
elevated dosage (150 mg/d) versus standard-dose ther-
apy  in  patients  with  proven  invasive  Candida infec-
tions,  mostly  candidemia  [43].  Both  dosages  were
equally well tolerated as shown in the primary safety
analysis. no significant differences between the study
arms were observed in terms of clinical or microbiogi-
cal response rates in the secondary efficacy analysis.
However, the trial was not sufficiently powered to es-
tablish either therapeutic noninferiority or superiority
of any treatment arm. a numerically higher response
rate of C. parapsilosis infections in the high-dose arm
(17/21 vs. 11/18) may indicate a benefit in patients
with this pathogen species but requires further study
due to the lack of statistical significance.
ExPERIEnCE In nEuTRoPEnIC PaTIEnTs
The therapeutic use of echinocandins in neutropenic
patients with invasive Candida infection has not been
studied in dedicated prospective trials. The echinocan-
din arms of the pivotal invasive candidiasis trials in-
cluded comparatively small numbers of patients with
neutropenia at baseline (3-50 patients, or 2.4%-13.3%)
[45, 55-57]. Keeping the limited database in mind, the
pooled response rate for neutropenic patients reported
in the trial of micafungin vs. caspofungin was in the
same range as in non-neutropenic patients (68% vs.
74%),  without  significant  differences  between  the
study  arms  [45].  Micafungin  achieved  a  similar  re-
sponse rate in neutropenic patients as did liposomal
amphotericin B (75% vs. 80% in the per protocol set
of the trial) [57]. Caspofungin was similarly effective
as  amphotericin  B  deoxycholate  in  neutropenic  pa-
tients (50% vs. 40% successfully treated patients) [56]. 
Betts  et  al.  [64]  published  a  compiled  analysis  of
neutropenic patients treated in 4 studies of the caspo-
fungin clinical trials program. overall success rate in
the 27 patients with invasive candidiasis was 68%, 15
of 17 successfully treated patients achieved a complete
response.
dEEsCalaTIon To azolEs
Based on the results of the pivotal trials of echinocan-
dins that all but one [57] allowed for a switch from in-
travenous echinocandin to (oral) therapy with flucona-
zole after 10 days, a step down to an oral azole agent
appears feasible after pathogen clearance and clinical
stabilization [65]. no detrimental effects of this step
down were observed in the approximately 20-35% of
the study patients using this option [45, 55, 56]. 
This approach may provide economic benefits and
helps to avoid changes of fungal epidemiology and se-
lection of echinocandin resistance via reduced overall
exposure to this class of drugs [66]. 
Prerequisites for a step down to an azole include
clinical  improvement,  resolution  of  fever,  negative
blood  culture,  documented  sensitivity  of  the  initial
isolate to the intended drug (particularly in patients
with C.  glabrata infection) and, in the case of oral
medication, adequate gastrointestinal function. Pivotal
trials that allowed a transition to an oral azole (flu-
conazole)  required  10  days  of  intravenous  therapy
[45, 55, 56]. The candidiasis guideline committee of
the  Infectious  diseases  society  of  america  (Idsa)
estimates that 3-5 days of echinocandin therapy fol-
lowed by oral fluconazole or voriconazole is reason-
able while pointing out that few data support this ap-
proach [67]. Therefore, the minimum required dura-
tion of an initial echinocandin therapy remains uncer-
tain.
CaTHETER ManagEMEnT
as biofilms forming on the surfaces of intravenous
catheters may serve as a source or reservoir in Candida
blood  stream  infections,  current  guidelines  recom-
mend the removal of catheters in patients with docu-
mented candidemia if at all possible [67]. However, as
cited by the Idsa guideline panel this recommenda-
tion is based primarily on experience in patients re-
ceiving antifungals other than echinocandins [67]. 
azoles, for that matter, exhibit very little or no use-
ful activity against Candida  spp. in biofilms [68, 69].
But as echinocandins have been shown to exert potent
antifungal  activity  against  biofilm-dwelling  Candida
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Fig. 1. global success rates in the anidula-
fungin ICE trial in intensive care patients
and the previous pivotal trial [55, 60, 61].
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urgency of early catheter removal into perspective. In-
terestingly, additive effects of neutrophils and anidula-
fungin  on  C.  parapsilosis and  C.  albicans biofilms
were recently reported [73, 74].
analyzing data from the two above-mentioned piv-
otal trials of micafungin vs. caspofungin or liposomal
amphotericin B, respectively, nucci et al. [75] did not
find  a  clinical  benefit  of  early  catheter  removal.  In
their multivariate analysis, early catheter removal with-
in 24 or 48 hours of treatment initiation was not asso-
ciated with higher treatment success or lower mortali-
ty. In two of the pivotal trials, response rates of pa-
tients  with  retained  catheters  were  similar  to  those
with catheter removal [56, 57]. In the study of mica-
fungin  vs.  caspofungin,  patients  who  underwent
catheter removal or replacement at any time had sig-
nificantly  higher  response  rates  than  those  with  re-
maining catheters in place [45]. This result of an unad-
justed  analysis  may  have  been  influenced  by  imbal-
ances of the severity of underlying diseases between
the  two  catheter  status  subgroups.  In  the  trial  of
anidulafungin  vs.  fluconazole,  the  response  rates  of
patients  with  retained  catheter  were  higher  in  the
anidulafungin group, whereas the number of patients
was small (4 vs. 11 patients) [55].
with  due  caution,  it  may  be  concluded  that  an
echinocandin could be preferred over fluconazole as
initial therapy for patients in whom early catheter re-
moval appears to be unfeasible or associated with in-
appropriate risks or complications. deescalation to an
azole appears inadequate in these patients. 
However, it should be noted that the guideline pan-
el  of  the  European  Conference  on  Infections  in
leukemia (ECIl-3) strongly recommends catheter re-
moval in all infections involving C. parapsilosis proba-
bly because this species is particularly prone to biofilm
formation and generally less susceptible to echinocan-
dins vs. other species [76]. 
ExPERIEnCE In PEdIaTRIC PaTIEnTs wITH
InvasIvE CAndidA InfECTIons
limited available data on the use or echinocandins for
treatment of invasive Candida infections in pediatric
patients  include  prospective  clinical  trials  for  caspo-
fungin and micafungin. Both agents are licensed for
the treatment of invasive candidiasis in children (>12
months of age for caspofungin). 
Caspofungin was studied in a multicenter trial that
involved 37 patients (age: 3 months to 17 years) with
invasive  Candida infections,  mostly  candidemia  [77].
In 30 patients with primary therapy, complete respons-
es were observed in 81% of cases. five of 7 patients
receiving  caspofungin  for  salvage  therapy  were  suc-
cessfully treated. The response rates were largely inde-
pendent of age, but the small sample size does not al-
low valid conclusions regarding this aspect. Two out
of five neutropenic patients were successfully treated.
In 4 patients, the dosage was escalated from 50 to 70
mg/m2 due  to  inadequate  treatment  response,  with
successful outcome in 3 of them. 
The  efficacy  of  micafungin  in  pediatric  patients
with invasive candidiasis was investigated in a subpop-
ulation  of  the  above-mentioned  double-blind,  ran-
domized trial. This substudy [78] compared micafun-
gin  (2  mg/kg)  with  liposomal  amphotericin  B  (3
mg/kg) as first-line therapy of invasive candidiasis in
106 children and adolescents <16 years of age; 57 pa-
tients were ≤2 years old, 19 patients were premature
infants. successful outcomes were observed in 73% of
patients of the micafungin group versus 76% of those
treated with liposomal amphotericin B. Treatment suc-
cess was independent of neutropenia or prematurity
status.  adverse  events  leading  to  discontinuation  of
study drug were significantly less frequent in the mica-
fungin group. 
Pediatric patients aged ≥6 months were included in
a randomized trial investigating prophylaxis of inva-
sive fungal infections in recipients of blood stem cell
transplants [46]. a total of 84 pediatric patients (<16
years), mostly receiving allogeneic hematopoietic stem
cell transplantation (HsCT) were analyzed. Proven or
probable breakthrough infections occurred in 1 of 39
pediatric patients in the micafungin group (no Candida
infections) and 3 of 45 in the fluconazole group (in-
cluding 1 candidemia).
Published clinical experience with anidulafungin in
children is limited to date [79]. Clinical trial data of
anidulafungin in pediatric patients with invasive can-
didiasis have not been presented yet; a non-compara-
tive trial enrolling 60 patients with invasive candidiasis
is ongoing [80].
Echinocandins, i.e. currently caspofungin and mica-
fungin, provide valuable and well-tolerated treatment
options for pediatric patients with Candida infections. 
PRoPHylaxIs of InvasIvE CandIdIasIs
Prophylactic use of systemic antifungals is an estab-
lished  practice  in  hematological  and  selected  non-
hematological patients at high risk of invasive candidi-
asis or other invasive fungal infections [81, 82]. several
studies have explored the use of echinocandins in this
indication.    
Clinical  experience  in  the  prophylactic  treatment
with caspofungin includes hematological patients and
liver  transplant  recipients.  Mattiuzzi  et  al.  [83]  per-
formed  an  open-label  randomized  comparison  of
caspofungin versus itraconazole in 192 patients receiv-
ing  chemotherapy  for  malignant  haematological  dis-
eases.  seven  patients  in  the  caspofungin  arm  devel-
oped invasive fungal infections (including 2 with can-
didemia), compared to 5 in the itraconazole arm (in-
cluding 4 with candidemia). The limited size of the tri-
al precluded definitive conclusions about the relative
prophylactic efficacy of both drugs. Chou et al. [84]
reported on a retrospective analysis of 123 blood stem
cell  recipients  (117  with  allogeneic  HsCT;  50  of
whom  developed  gvHd)  who  had  received  caspo-
fungin  (35-50  mg/d)  over  a  median  duration  of  73
days for prophylaxis of invasive fungal disease. nine
patients (7.3%) developed breakthrough invasive fun-
gal  infections  including  2  with  Candida infections).
The authors concluded that caspofungin appears to be
an effective option for primary antifungal prophylaxis
in the highly immunosuppressed stem cell transplant
patient  population.  fortun  et  al.  [85]  described  a
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ing prophylactic caspofungin for at least 21 days, the
observation  period  spanned  100  days.  Two  patients
developed  breakthrough  fungal  infection  including
one C. albicans surgical wound infection. 
Micafungin  was  investigated  in  a  large  phase  III
randomized double blind trial versus fluconazole for
prophylaxis in 882 allogeneic HsCT recipients of all
ages during the neutropenic phase for up to 42 days.
seven breakthrough infections occurred in the mica-
fungin arm (including 4 candidemias) versus 11 in the
fluconazole  group  (including  2  candidemias)  [46].
Based on the results of this trial, micafungin was li-
censed for prophylaxis of invasive Candida infections
in allogeneic HsCT patients. 
The prophylactic use of anidulafungin has not been
investigated as yet. 
Thus,  randomized  trials  on  prophylaxis  with
echinocandins indicate their potential usefulness in the
prevention of Candida infection in hematological high
risk patients. However, study data in non-hematologi-
cal  patients  are  insufficient  to  support  prophylactic
treatment with echinocandins in non-study settings for
this population. In addition, their routine prophylactic
use would expose high numbers of patients to these
agents for prolonged periods of time with potential
untoward consequences, e.g. selection of resistance in
the exposed patients, and shifts in the local epidemiol-
ogy  towards  less  echinocandin-susceptible  strains.
given the restricted options for the treatment of pa-
tients after exposure to echinocandins and/or selec-
tion  of  low-susceptibility  strains,  particularly  C.
glabrata and C.  krusei, the widespread use of these
agents appears unjustified, let alone the burden of in-
travenous application and high cost.
safETy and TolERaBIlITy
The  echinocandins  have  generally  favourable  safety
and tolerability profile (Table 2). Most observed ad-
verse events (aEs) are mild to moderate in nature. The
most  frequent  adverse  events  include  infusion  reac-
tions (predominantly phlebitis and fever), liver enzyme
abnormalities,mildhypokalemia,gastrointestinal symp  -
toms, skin rash and headache [29, 41, 91]. 
Infusion reactions such as fever or rigors that may
occur more often with caspofungin versus the other
echinocandins [86] may be managed by reducing the
rate of infusion. Phlebitis may be avoided by infusion
via a central venous catheter [54] after early replace-
ment in the course of therapy. liver enzyme abnor-
malities are generally mild and were mostly less com-
mon or similarly frequent as in the comparator groups
of randomized trials [55-57]. 
Echinocandins are rated as pregnancy category C
drugs and should not be used in pregnant women [87-
89].  as  these  drugs  may  be  secreted  in  the  milk,
breastfeeding should be avoided.    
In the pivotal trial of anidulafungin vs. fluconazole,
the total adverse event rates were similar in both arms
[55].  anidulafungin  was  associated  with  significantly
lower  incidence  of  hepatic  enzyme  abnormalities
(1.5% vs. 7.2% of patients; p = 0.03). Two patients ex-
perienced treatment-related serious aEs in the anidu-
lafungin arm (1 patient with atrial fibrillation, 1 with
seizures).  The  most  frequent  treatment  related  aEs
(all grades) were hypokalemia (3.1%), diarrhea (3.1%)
and elevated alT levels (2.3%). There was 1 treatment
discontinuation (<1%) due to an adverse event [90].
as  expected,  caspofungin  was  significantly  better
tolerated than amphotericin B deoxycholate in the piv-
otal invasive candidiasis trial [56]. drug-related infu-
sion reactions, laboratory abnormalities and nephro-
toxic  events  were  significantly  less  frequent  in  the
caspofungin group: 20% (vs. 49%) of patients had an
infusion-related  event  (mostly  chills,  fever  or
phlebitis/thrombophlebitis), 11% (vs. 26%) developed
hypokalemia  requiring  supplementation,  24%  (vs.
54%) developed laboratory abnormalities (mostly liver
function  test  changes)  and  8%  (vs.  25%)  had  a
nephrotoxic effect. Three percent (vs. 23%) discontin-
ued study treatment due to adverse events.
Micafungin  showed  a  generally  similar  safety  and
tolerability profile versus liposomal amphotericin B in
the first phase III trial in invasive candidiasis [57]. 5%
(vs. 9%) of patients discontinued therapy due to an
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Table 2. frequencies of drug-related adverse events observed in patients receiving echinocandins [86]. 
Adverse reaction, % of patients Anidulafungin Caspofungin Micafungin
Phlebitis < 1 3.5-25 1.6
fever < 1 4-40 1-14
abdominal pain < 2 3.6 1
nausea / vomiting 1 / < 1 1-6 / 2-4 2-7 / 1-5
diarrhea 3.1 3.6 1.6
Headache 1.3 4-15 2-17
Rash / pruritus 1 / <2 1-10 / < 2 1-12 / <1
leukopenia  < 1 6.2 1.6
neutropenia 1 1.9 1.2
Thrombocytopenia < 2 3.1 < 1
Hypokalemia 3-10 2-10 1.2
liver function test abnormalities 3-5 1-15 1-8
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aEs were infusion related reactions (17%), fever (8%),
hypokalemia (7%) and nausea (5%). drug-related lab-
oratory abnormalities mostly included moderate liver
function test abnormalities (2-7%). The second pivotal
trial comparing micafungin vs. caspofungin reported
similar overall drug-related aE profiles in the two mi-
cafungin and the caspofungin arms [45]. The types of
adverse events were not reported per treatment group
in the publication. adverse events in the total popula-
tion predominantly included liver function test abnor-
malities, nausea, constipation, hypokalemia and rash;
2-4% of patients withdrew from the trial due to ad-
verse events.
as a unique aspect or micafungin, foci of altered
hepatocytes  and  hepatocellular  tumours  were  ob-
served after prolonged exposure in preclinical animal
experiments, with a threshold for tumour induction in
the range of human therapeutic exposure [91]. while
the  clinical  relevance  of  these  findings  remains  un-
clear, the European Medicines agency restricted the
use of micafungin to situations where other antifun-
gals are inappropriate. Treatment should be discontin-
ued  in  patients  with  elevation  of  liver  enzymes  on
therapy to avoid adaptive liver cell regeneration and
potential subsequent tumour formation. Taking a di-
vergent view on the apparent preclinical tumorigenici-
ty of prolonged exposure to micafungin, the food and
drug administration did not impose this kind of re-
striction [92].
RECoMMEndaTIons In guIdElInEs
Based on the results of the described clinical trials, an
expert  group  of  the  Infectious  disease  society  of
america [67] recommends echinocandins as the pre-
ferred treatment in moderately to severely ill non-neu-
tropenic adult patients with suspected or documented
candidemia before pathogen species identification. In
particular, the Idsa committee recommends the use
of anidulafungin, caspofungin or micafungin at an evi-
dence level of a-I. fluconazole should be restricted to
less severely ill patients without recent exposure to an
azole antifungal, and those patients without an elevat-
ed  risk  of  involvement  of  C.  glabrata or  C.  krusei
(such  as  cancer  patients  or  elderly  patients)  [93-95].
for  infections  with  documented  involvement  of  C.
glabrata, the Idsa panel recommends an echinocan-
din, whereas fluconazole is preferred for documented
C. parapsilosis infections. In terms of prophylaxis, mi-
cafungin at 50 mg/d is considered an option for allo-
geneic stem cell recipients with neutropenia (evidence
level a-I). 
on a conference in 2009, European Conference on
Infections in leukemia (ECIl-3) panel issued similar
guidance [76, 96]: echinocandins or liposomal ampho-
tericin B are recommended with the highest assigned
evidence  level  for  treatment  of  candidemia  before
species identification in the general patient population
and  in  hematologic  patients.  azoles  should  not  be
used in patients with previous azole prophylaxis, and
fluconazole  is  restricted  to  non-severely  ill  patients.
after species identification, echinocandins or liposo-
mal amphotericin B are treatments of choice in pa-
tients infected with C.  albicans, C.  glabrata, and C.
krusei. fluconazole should not be used for C. glabrata
and C. krusei infections. There is no guidance provid-
ed on preferred treatments for C.  parapsilosis infec-
tions.
In  their  guidelines  for  hematological  patients,  the
Infectious diseases working Party (agIHo) of the
german  society  of  Hematology  and  oncology
(dgHo) prefers an echinocandin to fluconazole for
initial  therapy  of  invasive  candidiasis  in  unstable  or
neutropenic  patients.  This  recommendation  is  based
on the increasing incidence of infections with Candida
spp. with primary resistance or reduced susceptibility
to fluconazole and its lower efficacy versus anidula-
fungin [55, 97]. 
while  the  optimum  treatment  duration  has  not
been specifically studied, the guideline panels recom-
mended a duration of therapy for candidemia without
obvious metastatic complications of at least 2 weeks
after documented eradication of Candida species from
the bloodstream plus resolution of symptoms attribut-
able to candidemia plus resolution of neutropenia, if
applicable [67, 76, 96, 97]. 
RolE of THE ECHInoCandIns In THE
ManagEMEnT of InvasIvE CAndidA
InfECTIons
The echinocandins combine a number of features re-
quired for the optimization of primary therapy of in-
vasive Candida infections, providing enhanced oppor-
tunities of effective and safe treatment over the azole
antifungals, particularly fluconazole that is still used as
primary therapy in the majority of patients with can-
didemia (Table 3; fig. 2) [98].
In contrast to the azoles they are fungicidal against
most  Candida strains  [20],  potentially  allowing  for
more rapid clearance of the pathogen from the infec-
tion sites. while fungicidality may prove advantageous
in severely ill patients, particularly those with severe
sepsis, this could not yet be demonstrated in clinical
studies since the proportion of critically ill patients in
the only available trial of an echinocandin vs. an azole
in this indication was below 20%. at least for anidula-
fungin, a significantly higher success rate in the prima-
ry endpoint of a randomized trial versus fluconazole
indicates potential therapeutic advantages of echino  -
candins  over  azoles  in  the  treatment  of  candidemia
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Table 3. agents used for the treatment of candidemia as reported in the PaTH alliance database [98]. 
n = 2019 patients  Fluconazole Echinocandins Lipid-formulation  Voriconazole Amphotericin B 
amphotericin B deoxycholate
Patients treated, % 67.7 48.9 10.0 6.7 2.2
5) Gloeckner_Umbruchvorlage  23.03.11  12:35  Seite 174[55].  also  evidence  of  a  shortened  median  time  to
blood  culture  negativity  vs.  fluconazole  appears  to
point in that direction [59].
Being fully active against C. glabrata and C. krusei,
the fungal achillesﾴ heels of fluconazole, the echino  -
candins  provide  an  important  measure  of  additional
therapeutic  reliability  in  situations  where  treatment
must be started in absence of species identification or
even before availability of blood culture results, partic-
ularly in elderly patients with high rates of C. glabrata
infection  [94],  and  for  hematologic  and  solid  cancer
patients in whom very high rates of fluconazole-resis-
tant  isolates  have  been  described  in  a  recent  can-
didemia survey [95]. again, this is particularly relevant
in patients with severe sepsis or septic shock with a
narrow time window of opportunity for initiation of
effective therapy to preserve optimum chances of sur-
vival [99, 100].
Elevated inhibitory concentrations observed in C.
parapsilosis are causing some concern, but several as-
pects may alleviate these concerns: (i) a meta-analysis
revealed no disadvantage for echinocandins vs. other
therapies; [22] (ii) C. parapsilosis is considered as a less
virulent compared to e.g. C. albicans and is associated
with lower mortality rates [98], (iii) recently proposed
resistance breakpoints for C.  parapsilosis are several
steps higher than for the other clinically relevant Can-
dida species [23]; and (iv) current guidelines recom-
mend  echinocandins  for  primary  therapy  in  the  ab-
sence of species information [67, 76, 97]. 
organ dysfunctions are common in patients devel-
oping invasive fungal infections. Being pharmacokinet-
ically independent of renal function, the echino  candins
need no dose adjustment in patients with all grades of
renal insufficiency or renal replacement therapies, quite
different  from  fluconazole  that  needs  complex  dose
adjustments  in  patients  with  impaired  renal  function
and hemodialysis or hemofiltration [101]. In fact, renal
impairment was identified as a significant predictor of
inadequate fluconazole dosing [102].
In  patients  with  liver  dysfunction,  anidulafungin
and micafungin may be administered without dose ad-
justments [41, 47]. anidulafungin can be used in pa-
tients with severe hepatic insufficiency [41]. The other
echinocandins should not be used in this population
for lack of data. 
The low propensity of echinocandins for drug in-
teractions may allow for substantial simplification of
treatment  in  severely  ill  patients  receiving  multiple
comedications. Being inhibitors and substrates of he-
patic enzymes, the azoles are associated with a multi-
tude of interactions [103] complicating patient man-
agement  and  potentially  jeopardizing  treatment  suc-
cess.  This  issue  is  avoided  with  anidulafungin  and
greatly reduced to interactions with few immunosup-
pressive drugs with the other echinocandins.
activity  against  biofilms  is  another  feature  that
favours  the  echinocandins  over  azoles  as  agents  of
choice in patients with catheter-associated candidemia
particularlyinsituationswhereearlyremoval of catheters
appears  unfeasible.  Even  in  patients  whose  catheters
are  removed  within  the  first  two  days  of  therapy,
echinocandins may suppress fungal burden more effec-
tively during this critical initial treatment phase when
the potentially fungus-shedding device is still present. 
Prophylactic use of echinocandins currently is an
option  for  selected  hematological  patients  in  whom
azoles are inappropriate due to tolerability issues or
unmanageable  drug  interactions.  Mind  that  anidula-
fungin and caspofungin are not licensed for prophy-
laxis and micafungin is not licensed for prophylaxis of
mould infections, a predominant concern in hemato-
logical patients [29, 41, 47]. 
In conclusion, echinocandins provide safe, uncom-
plicated and highly active therapy for invasive Candida
infections with potentially superior efficacy versus flu-
conazole and better tolerability compared to formula-
tions of amphotericin B, making them the agents of
choice for moderately to severely ill patients with inva-
sive candidiasis. 
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Fig.  2. Place of echino  candins in the pri-
mary  treatment  of  invasive  can  didiasis in
adult non-neutropenic  patients.  Modified
algorithm based on current guidelines [67].
*  Hemodynamic  instability  and/or  sin-
gle/multiple organ failure, i.e. most patients
on intensive care units.
** Clinical improvement, resolution of clin-
ical and paraclinical signs of inflammation,
initial isolate susceptible to fluconazole or
voriconazole,  adequate  gastrointestinal
function for absorption.
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